From the publishers of JADPRO

Acute Lymphoblastic Leukemia Resource Center

Advertisement

Treatment-free remission in nontransplanted patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

Last Updated: Tuesday, July 1, 2025

Researchers investigated the safety and feasibility of discontinuing tyrosine kinase inhibitor (TKI) therapy in a select group of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia who have achieved complete molecular response (CMR) without undergoing allogeneic stem cell transplantation. The study retrospectively analyzed 14 patients, finding that 79% maintained treatment-free remission after TKI discontinuation, particularly those with a CMR duration exceeding 48 months.

Cancer
Advertisement
News & Literature Highlights
Advertisement
Advertisement